

# Rangi K Kandane-Rathnayake

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/189865/rangi-k-kandane-rathnayake-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23  
papers

420  
citations

12  
h-index

20  
g-index

26  
ext. papers

616  
ext. citations

4.9  
avg, IF

3.39  
L-index

#	Paper	IF	Citations
23	Not at target prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 70	5.7	1
22	POS0028 DEFINING THE PREVALENCE OF UNMET NEED IN SLE: DATA FROM A LARGE MULTINATIONAL LONGITUDINAL SLE COHORT. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 218-219	2.4	
21	Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study. <i>Lupus</i> , <b>2021</b> , 30, 1586-1595	2.6	1
20	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , <b>2021</b> , 60, 5185-5193	3.9	1
19	Clinician-reported outcome measures in lupus trials: a problem worth solving. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e595-e603	14.2	1
18	Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 8	5.7	16
17	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e24-e30	14.2	22
16	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 1255-1257	2.3	9
15	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1289-1295	4.7	12
14	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology, The</i> , <b>2019</b> , 1, e95-e102	14.2	26
13	Outcomes of patients admitted to hospital medical units with back pain. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 316-322	1.6	5
12	Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. <i>Lupus</i> , <b>2019</b> , 28, 1669-1677	2.6	4
11	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 425-433	2.3	14
10	Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2018</b> , 8, 3268	4.9	12
9	Discordance of patient and physician health status concerns in systemic lupus erythematosus. <i>Lupus</i> , <b>2018</b> , 27, 501-506	2.6	35
8	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 62	5.7	59
7	The Dose-Response Association between Nitrogen Dioxide Exposure and Serum Interleukin-6 Concentrations. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	22

6	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 260	5.7	29
5	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2016</b> , 6, 34604	4.9	53
4	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2016</b> , 6, 29909	4.9	22
3	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000157	4.6	53
2	The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. <i>Blood Transfusion</i> , <b>2015</b> , 13, 86-99	3.6	22
1	Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. <i>ANZ Journal of Surgery</i> , <b>2013</b> , 83, 155-60	1	1